Equities Analysts Set Expectations for PDSB FY2024 Earnings

PDS Biotechnology Co. (NASDAQ:PDSB) – Equities researchers at B. Riley lowered their FY2024 EPS estimates for PDS Biotechnology in a report issued on Monday, November 25th. B. Riley analyst M. Mamtani now forecasts that the company will earn ($1.12) per share for the year, down from their prior estimate of ($1.06). B. Riley has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.18) per share. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

A number of other research analysts also recently weighed in on PDSB. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a research report on Friday, November 15th. Finally, Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Trading Up 1.9 %

NASDAQ PDSB opened at $2.15 on Wednesday. The firm’s 50 day moving average price is $3.06 and its two-hundred day moving average price is $3.17. The stock has a market cap of $80.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.93. PDS Biotechnology has a twelve month low of $1.53 and a twelve month high of $6.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after purchasing an additional 37,142 shares in the last quarter. Inspirion Wealth Advisors LLC lifted its holdings in shares of PDS Biotechnology by 1.4% during the 2nd quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after buying an additional 4,917 shares during the last quarter. Blair William & Co. IL grew its stake in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after buying an additional 81,743 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after buying an additional 47,528 shares during the last quarter. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.